Tobacco use is still a neglected cancer risk factor in Asia
Tailored strategies based on existing technologies and digital tools are needed to help inform people in geographically difficult-to-reach communities
Rare cancers in Asia – the value of registry data in low-resourced settings
While some challenges associated with rare cancers are similar in Europe and Asia, resources and differing epidemiology need to be considered when coming up with solutions
Equity among oncologists is far from being achieved in the Chinese culture
Results from a pilot study show that work–family balance is the biggest challenge to career progression for young women
Cancer Control Principles
Disclose or not disclose – COIs mismanagement erodes public trust
There is a broader negligence of the public health consequences of individual actions among the health providers
A study reveals the clonal heterogeneity of de novo metastatic castration-sensitive prostate cancer
Findings suggest that analysis of multiple prostate diagnostic biopsy cores, in contrast to frequent practice, may help reduce tumour mischaracterisation and identify genetic alterations relevant to personalised treatment
Combining liquid biopsy technologies may help improve tumour monitoring
Results from two studies suggest that this approach is essential to refining liquid biopsy use in early cancer detection and to check tumour progression
Should cancer therapy be tailored based on receptor tyrosine kinase alterations?
Data from a molecular analysis of receptor tyrosine kinase-mutated cancers show a wide heterogeneity of alterations and response to tyrosine kinase inhibitor monotherapy
Dynamic immunoediting of tumours may hold the clue to effective treatment with immunotherapy
Success of immunotherapy is tied to tumour evolution from early- to late-stages, as a study in non-small-cell lung cancer highlights
Molecular cancer early detection and prevention - an attainable goal?
Adoption of molecular-based early detection techniques in clinical practice depends on the success of large-scale clinical studies and cost barriers
New targets for off-the-shelf treatments open up the field of precision immunotherapy
The identification of mutation-derived neoantigens may help elicit antitumour immune responses in patients with cancer, but this approach is challenging